Nanotechnology-COVID-19 Interface

By: Devasena T.

Write A Review

eText | 3 February 2021

At a Glance

Format
ePUB

eText

$89.00

or 4 interest-free payments of $22.25 with

Instant online reading in your Booktopia eTextbook Library *

Why choose an eTextbook?

Instant Access *

Purchase and read your book immediately

Read Aloud

Listen and follow along as Bookshelf reads to you

Study Tools

Built-in study tools like highlights and more

* eTextbooks are not downloadable to your eReader or an app and can be accessed via web browsers only. You must be connected to the internet and have no technical issues with your device or browser that could prevent the eTextbook from operating.

This book highlights the role of nanotechnology concepts in the management of COVID-19 pandemic. The book covers different aspects of the causative agent SARS CoV2 (Severe Acute Respiratory Syndrome Coronavirus-2) and the COVID-19 pandemic with a special emphasis on nanotechnology. It discusses the origin and history of SARS CoV2 and the outbreak of COVID-19 and highlights the geographical mutations in the SARS CoV2 virus genome, providing information about the structural features, antigenicity and the life cycle of SARS CoV2. The book provides an insight into nanotechnology-virology interface and explains how nanomaterials link the gap between the vital phases of SARS CoV2 life cycle and the four modalities of COVID-19 management viz sensing/diagnosis, therapy, prevention and self-protection. Further, the existing and promising diagnostic tools for detection of COVID-19 are discussed with an emphasis on nano PCR, nanoimmunosensors, biobarcode assay and point of care approach and also describe the nanoparticles involved in the CT imaging of lungs and SFHI (Spatial Frequency Hetrodyne Imaging) for diagnosis of SARS COV2 infection. The book concludes with details about translational medicine and explains the types of SARS CoV2 vaccines, stages of COVID-19 vaccine development and possible nanovaccines for COVID-19, followed by the description on biopharmaceutical companies involved in the production of SARS CoV2 vaccines.